United Therapeutics will deliver eight presentations at the European Society of Cardiology (ESC) Congress 2026 and the European Respiratory Society (ERS) International Congress 2026. These include four oral and four poster presentations. The sessions feature late-breaking analyses from pivotal clinical trials for the company’s primary drug candidates.
Presentations will highlight findings from the Phase 3 ADVANCE OUTCOMES study of ralinepag for pulmonary arterial hypertension (PAH). The company will also share data from the Phase 3 TETON program for nebulized treprostinil in idiopathic pulmonary fibrosis (IPF).
United Therapeutics submitted a New Drug Application for ralinepag to the FDA in June 2026. It filed a supplemental NDA for nebulized treprostinil during the same month. These analyses provide the medical community with data on the efficacy and safety of treatments for life-threatening lung diseases.